{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:30:06Z","timestamp":1792207806766,"version":"4.4.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Few data inform implementation of emerging state-regulated psilocybin programs.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The Open Psychedelic Evaluation Nexus (OPEN) aims to assess the safety and participant outcomes of Oregon\u2019s regulated psilocybin services.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included psilocybin clients enrolled between November 2024 and March 2026, with follow-up through June 2026, at 24 of 26 Oregon psilocybin service centers with active licenses. Eligible participants were consenting Oregon psilocybin services clients supervised by 83 licensed psilocybin facilitators. OPEN\u2019s client-facing platform collects confidential data at baseline and at 1 week, 1 month, and 3 months after psilocybin sessions supported by licensed facilitators.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Receipt of Oregon psilocybin services.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Facilitator-reported psilocybin dose (in milligrams) and safety events during psilocybin session. Participant-reported depression (measured by the Patient Health Questionnaire-9), anxiety (Hospital Anxiety and Depression Scale), and PTSD (6-item PTSD Checklist [PCL-6]) symptoms; mental well-being; life satisfaction; harms; overall benefit; meaning; and services satisfaction.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total 346 participants were included (mean [SD] age, 49.5 [13.4] years; 181 women [52.5%]; 15 Asian [4.5%], 300 White [89.0%], 12 multiple races [3.6%]); 19 participants (5.5%) identified as veterans, 262 (76.6%) completed college, and 89 (29.0%) had a household income above $200\u202f000. Reported substance use in the past 30 days was 203 (58.7%) for alcohol, 38 (11.0%) for nicotine or tobacco, and 127 [36.7%] for cannabis use; 44.2% were psychedelic-naive and received a mean (SD) psilocybin dose of 31.9 (11.2) mg. Retention was 93.1% at 1 week (322 participants), 92.8% at 1 month (321 participants), and 90.2% at 3 months (312 participants). Four individuals (1.2%, all psychedelic-naive) experienced adverse behavioral reactions requiring medical attention. Few participants reported their psilocybin experience as harmful (5 of 305 [1.6%] at 1 week, 6 of 321 [1.9%] at 1 month, and 7 of 312 [2.3%] at 3 months). At 1 month, 92.2% (296 of 321 participants) felt they benefited, and 58.6% (188 of 321 participants) ranked the experience among the 10 most meaningful of their life. At 3 months, participants reported decreased moderate-to-severe symptoms of depression (relative risk [RR], 0.40; 95% CI, 0.32-0.50), anxiety (RR, 0.29; 95% CI, 0.22-0.38), and PTSD symptoms (RR, 0.35; 95% CI, 0.27-0.45), and improved mental well-being (mean difference in Short Warwick-Edinburgh Mental Well-being Scale\u2009=\u20093.21; 95% CI, 2.66-3.76), and life satisfaction (RR, 1.31; 95% CI, 1.19-1.44) compared with baseline. Serious adverse reactions were uncommon, although clinically significant.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this multisite cohort of participants receiving state-regulated psilocybin services in Oregon, serious adverse reactions were uncommon. Most participants reported improvements in mental health, wellness, and life satisfaction. Longitudinal findings support safety and potential benefits that can inform clinicians, policymakers, and the public as other state-regulated psychedelic services emerge.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.30608","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:30:52Z","timestamp":1787153452000},"page":"e2630608","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services"],"prefix":"10.1001","volume":"9","author":[{"given":"P. Todd","family":"Korthuis","sequence":"first","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan R.","family":"Cook","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Gregoire","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Stauffer","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"},{"name":"VA Portland Healthcare System, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason B.","family":"Luoma","sequence":"additional","affiliation":[{"name":"Portland Institute for Psychedelic Science, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie","family":"Pertl","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Des Jarlais","sequence":"additional","affiliation":[{"name":"New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena A.","family":"Levander","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne R.","family":"Wilson-Poe","sequence":"additional","affiliation":[{"name":"Legacy Research Institute, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"1","key":"zoi260833r3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-psych-020124-023532","article-title":"Therapeutic potential of psychedelic drugs: navigating high hopes, strong claims, weak evidence, and big money.","volume":"76","author":"Humphreys","year":"2025","journal-title":"Annu Rev Psychol"},{"key":"zoi260833r4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: a systematic review.","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi260833r5","doi-asserted-by":"publisher","DOI":"10.1097\/j.pbj.0000000000000128","article-title":"What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.","volume":"6","author":"Castro Santos","year":"2021","journal-title":"Porto Biomed J"},{"issue":"1","key":"zoi260833r6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamapsychiatry.2025.3038","article-title":"Psilocybin outside the clinic: public health challenges of increasing publicity, accessibility, and use.","volume":"83","author":"Hutchison","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"zoi260833r7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euroneuro.2025.09.011","article-title":"Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis.","volume":"101","author":"H\u00f8jlund","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"zoi260833r8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.7326\/ANNALS-24-03145","article-title":"The rise of psilocybin use in the United States: a multisource observational study.","volume":"178","author":"Rockhill","year":"2025","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi260833r9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jadohealth.2024.01.027","article-title":"Psilocybin exposures reported to U.S. poison centers: national trends over a decade.","volume":"74","author":"Farah","year":"2024","journal-title":"J Adolesc Health"},{"issue":"5","key":"zoi260833r10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/add.16432","article-title":"Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022.","volume":"119","author":"Garel","year":"2024","journal-title":"Addiction"},{"issue":"10","key":"zoi260833r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","article-title":"Extended difficulties following the use of psychedelic drugs: a mixed methods study.","volume":"18","author":"Evans","year":"2023","journal-title":"PLoS One"},{"key":"zoi260833r12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.831092","article-title":"Effects of naturalistic psychedelic use on depression, anxiety, and well-being: associations with patterns of use, reported harms, and transformative mental states.","volume":"13","author":"Raison","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi260833r13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US.","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi260833r15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis.","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi260833r16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41591-023-02727-4","article-title":"The safety of supported psilocybin use in Oregon.","volume":"30","author":"Smith","year":"2024","journal-title":"Nat Med"},{"key":"zoi260833r17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s44220-024-00233-1","article-title":"Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance.","volume":"2","author":"Black","year":"2024","journal-title":"Nat Ment Health"},{"issue":"8","key":"zoi260833r18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"16","key":"zoi260833r21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"issue":"2-3","key":"zoi260833r22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.drugalcdep.2006.09.002","article-title":"Initial evidence for the reliability and validity of a \u201clite\u201d version of the Addiction Severity Index.","volume":"87","author":"Cacciola","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"zoi260833r23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/02698811241257839","article-title":"Developing the Open Consensus Measures for Assessment of Supervised Psilocybin Services: an e-Delphi study.","volume":"38","author":"Korthuis","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"9","key":"zoi260833r24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi260833r25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/occmed\/kqu024","article-title":"The hospital anxiety and depression scale.","volume":"64","author":"Stern","year":"2014","journal-title":"Occup Med (Lond)"},{"issue":"4","key":"zoi260833r26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.genhosppsych.2012.02.003","article-title":"Abbreviated PTSD Checklist (PCL) as a guide to clinical response.","volume":"34","author":"Lang","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"issue":"10","key":"zoi260833r27","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1007\/s11136-014-0726-4","article-title":"Assessing the validity of single-item life satisfaction measures: results from three large samples.","volume":"23","author":"Cheung","year":"2014","journal-title":"Qual Life Res"},{"issue":"1","key":"zoi260833r28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12955-021-01882-x","article-title":"Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS): performance in a clinical sample in relation to PHQ-9 and GAD-7.","volume":"19","author":"Shah","year":"2021","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"zoi260833r30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/pnasnexus\/pgae560","article-title":"Predictors of hallucinogen persisting perception disorder symptoms, delusional ideation and magical thinking following naturalistic psychedelic use.","volume":"4","author":"Zhou","year":"2025","journal-title":"PNAS Nexus"},{"issue":"1","key":"zoi260833r31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1176\/appi.prcp.20240128","article-title":"On minimizing risk and harm in the use of psychedelics.","volume":"7","author":"Evans","year":"2025","journal-title":"Psychiatr Res Clin Pract"},{"key":"zoi260833r32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1049643","article-title":"Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: an initial exploratory analysis of the phenomenon\u2019s predictors and its emotional valence.","volume":"13","author":"Ortiz Bernal","year":"2022","journal-title":"Front Psychiatry"},{"key":"zoi260833r33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2025.2577305","article-title":"Reactivations associated with the use of 5-MeO-DMT among Spanish-speaking individuals: prevalence, predictors, and emotional valence.","author":"Ortiz Bernal","year":"2025","journal-title":"J Psychoactive Drugs"},{"key":"zoi260833r2","volume-title":"How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence","author":"Pollan","year":"2018"},{"key":"zoi260833r1","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2024 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2025. HHS Publication No. PEP25-07-007, NSDUH Series H-60. Accessed August 13, 2025. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56287\/2024-nsduh-annual-national\/2024-nsduh-annual-national-html-071425-edited\/2024-nsduh-annual-national.htm"},{"key":"zoi260833r14","unstructured":"Lineham? A, Hardman? J. Oregon Psilocybin Services Tracker. Accessed January 23, 2026. https:\/\/psychedelicalpha.com\/resources\/the-oregon-psilocybin-services-tracker\/"},{"key":"zoi260833r19","unstructured":"Oregon Health Authority. Oregon Psilocybin Services fact sheet. March 2024. Accessed January 23, 2026. https:\/\/www.oregon.gov\/oha\/PH\/PREVENTIONWELLNESS\/Documents\/OPS-Fact-Sheet.pdf"},{"key":"zoi260833r20","unstructured":"Oregon Health Authority. Oregon Psilocybin Services administrative rules. Accessed December 15, 2024. https:\/\/secure.sos.state.or.us\/oard\/displayDivisionRules.action?selectedDivision=7102"},{"key":"zoi260833r29","unstructured":"Oregon Health Authority. Psilocybin Administrative Rules 333-333\u2014Public Health Division, Chapter 333. 2025. Accessed January 31, 2026. https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=332023"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853028\/korthuis_2026_oi_260833_1791816149.70783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:00:18Z","timestamp":1792162818000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.30608","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}